1932
0
  1. Home
  2. A-Z Publications
  3. Annual Review of Pathology: Mechanisms of Disease
  4. Volume 12, 2017
  5. Article

Annual Review of Pathology: Mechanisms of Disease

Volume 12, 2017

Pathogenesis and Pathology of Mastocytosis

Abstract

Systemic mastocytosis is a clonal disorder of mast cells that may variably present with characteristic skin lesions, episodes of mast cell mediator release, and disturbances of hematopoiesis. No curative therapy presently exists. Conventional management has relied on agents that antagonize mediators released by mast cells, inhibit mediator secretion, or modulate mast cell proliferation. Recent advances in the molecular understanding of the pathophysiology of systemic mastocytosis have provided new therapeutic considerations, including new and novel tyrosine kinase inhibitors.

Keyword(s): KIT, mast cell mediators, mast cells, mastocytosis
Loading

Article metrics loading...

/content/journals/10.1146/annurev-pathol-052016-100312
2017-01-24
2025-04-20
Loading full text...

Full text loading...

/deliver/fulltext/pathol/12/1/annurev-pathol-052016-100312.html?itemId=/content/journals/10.1146/annurev-pathol-052016-100312&mimeType=html&fmt=ahah

Literature Cited

  1. Nettleship E, Tay W. 1.  1869. Rare forms of urticaria. Br. Med. J 2323–30 [Google Scholar]
  2. Sanger A. 2.  1878. An anomalous mottled rash, accompanied by pruritus, factious urticaria and pigmentation, “urticaria pigmentosa. .” Clin. Soc. Lond. 11:161–63 [Google Scholar]
  3. Unna P. 3.  1887. Beitrage zur Anatomie und Pathogenese der Urticaria simplex und pigmentosa. Mschr. Prakt. Dermatol. Suppl. Dermatol. Stud. 3:9 [Google Scholar]
  4. Ellis J. 4.  1949. Urticaria pigmentosa; a report of a case with autopsy. Arch. Pathol. 48:426–35 [Google Scholar]
  5. Horny H, Akin C, Arber DA, Peterson L, Tefferi A. 5.  et al. 2016. Mastocytosis. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues S Swerdlow, E Campo, N Harris Geneva: World Health Organ In press [Google Scholar]
  6. Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S. 6.  et al. 1995. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. PNAS 92:10560–64 [Google Scholar]
  7. Longley BJ, Tyrrell L, Lu SZ, Ma YS, Langley K. 7.  et al. 1996. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat. Genet. 12:312–14 [Google Scholar]
  8. Yavuz AS, Lipsky PE, Yavuz S, Metcalfe DD, Akin C. 8.  2002. Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene. Blood 100:661–65 [Google Scholar]
  9. Taylor ML, Sehgal D, Raffeld M, Obiakor H, Akin C. 9.  et al. 2004. Demonstration that mast cells, T cells, and B cells bearing the activating kit mutation D816V occur in clusters within the marrow of patients with mastocytosis. J. Mol. Diagn. 6:335–42 [Google Scholar]
  10. Akin C, Kirshenbaum AS, Semere T, Worobec AS, Scott LM. 10.  et al. 2000. Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis. Exp. Hematol. 28:140–47 [Google Scholar]
  11. Kirshenbaum AS, Kessler SW, Goff JP, Metcalfe DD. 11.  1991. Demonstration of the origin of human mast cells from CD34+ bone marrow progenitor cells. J. Immunol. 146:1410–15 [Google Scholar]
  12. Teodosio C, Mayado A, Sanchez-Muñoz L, Morgado JM, Jara-Acevedo M. 12.  et al. 2015. The immunophenotype of mast cells and its utility in the diagnostic work-up of systemic mastocytosis. J. Leukoc. Biol. 97:49–59 [Google Scholar]
  13. Sanchez-Munoz L, Teodosio C, Morgado JM, Escribano L. 13.  2011. Immunophenotypic characterization of bone marrow mast cells in mastocytosis and other mast cell disorders. Methods Cell Biol 103:333–59 [Google Scholar]
  14. Escribano L, Garcia Montero AC, Nunez R, Orfao A. 14. , Red Esp. Mastocitosis (REMA). 2006. Flow cytometric analysis of normal and neoplastic mast cells: role in diagnosis and follow-up of mast cell disease. Immunol. Allergy Clin. N. Am. 26:535–47 [Google Scholar]
  15. Teodosio C, Garcia-Montero AC, Jara-Acevedo M, Sanchez-Munoz L, Alvarez-Twose I. 15.  et al. 2010. Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes. J. Allergy Clin. Immunol. 125:719–26 [Google Scholar]
  16. Morgado JM, Sanchez-Munoz L, Teodosio CG, Jara-Acevedo M, Alvarez-Twose I. 16.  et al. 2012. Immunophenotyping in systemic mastocytosis diagnosis: ‘CD25 positive’ alone is more informative than the ‘CD25 and/or CD2’ WHO criterion. Mod. Pathol. 25:516–21 [Google Scholar]
  17. Chisholm KM, Merker JD, Gotlib JR, Gitana G, Lefterova M. 17.  et al. 2015. Mast cells in systemic mastocytosis have distinctly brighter CD45 expression by flow cytometry. Am. J. Clin. Pathol. 143:527–34 [Google Scholar]
  18. Morgado JM, Perbellini O, Johnson RC, Teodosio C, Matito A. 18.  et al. 2013. CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis. Histopathology 63:780–87 [Google Scholar]
  19. Schwartz LB. 19.  2006. Diagnostic value of tryptase in anaphylaxis and mastocytosis. Immunol. Allergy Clin. N. Am. 26:451–63 [Google Scholar]
  20. Metcalfe DD. 20.  2008. Mast cells and mastocytosis. Blood 112:946–56 [Google Scholar]
  21. Hartmann K, Wagner N, Rabenhorst A, Pflanz L, Leja S. 21.  et al. 2013. Serum IL-31 levels are increased in a subset of patients with mastocytosis and correlate with disease severity in adult patients. J. Allergy Clin. Immunol. 132:232–35 [Google Scholar]
  22. Gilfillan AM, Peavy RD, Metcalfe DD. 22.  2009. Amplification mechanisms for the enhancement of antigen-mediated mast cell activation. Immunol. Res. 43:15–24 [Google Scholar]
  23. Longley BJ Jr, Morganroth GS, Tyrrell L, Ding TG, Anderson DM. 23.  et al. 1993. Altered metabolism of mast-cell growth factor (c-kit ligand) in cutaneous mastocytosis. N. Engl. J. Med. 328:1302–7 [Google Scholar]
  24. Akin C, Jaffe ES, Raffeld M, Kirshenbaum AS, Daley T. 24.  et al. 2002. An immunohistochemical study of the bone marrow lesions of systemic mastocytosis: expression of stem cell factor by lesional mast cells. Am. J. Clin. Pathol. 118:242–47 [Google Scholar]
  25. Taylor ML, Dastych J, Sehgal D, Sundstrom M, Nilsson G. 25.  et al. 2001. The Kit-activating mutation D816V enhances stem cell factor–dependent chemotaxis. Blood 98:1195–99 [Google Scholar]
  26. Lee YN, Brandal S, Noel P, Wentzel E, Mendell JT. 26.  et al. 2011. KIT signaling regulates MITF expression through miRNAs in normal and malignant mast cell proliferation. Blood 117:3629–40 [Google Scholar]
  27. Miettinen M, Lasota J. 27.  2005. KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl. Immunohistochem. Mol. Morphol. 13:205–20 [Google Scholar]
  28. Furitsu T, Tsujimura T, Tono T, Ikeda H, Kitayama H. 28.  et al. 1993. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J. Clin. Invest. 92:1736–44 [Google Scholar]
  29. Feger F, Ribadeau Dumas A, Leriche L, Valent P, Arock M. 29.  2002. Kit and c-kit mutations in mastocytosis: a short overview with special reference to novel molecular and diagnostic concepts. Int. Arch. Allergy Immunol. 127:110–14 [Google Scholar]
  30. Longley BJ Jr, Metcalfe DD, Tharp M, Wang X, Tyrrell L. 30.  et al. 1999. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. PNAS 96:1609–14 [Google Scholar]
  31. Carter MC, Metcalfe DD, Clark AS, Wayne AS, Maric I. 31.  2015. Abnormal bone marrow histopathology in paediatric mastocytosis. Br. J. Haematol. 168:865–73 [Google Scholar]
  32. Jawhar M, Schwaab J, Schnittger S, Meggendorfer M, Pfirrmann M. 32.  et al. 2016. Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V+ advanced systemic mastocytosis. Leukemia 30:136–43 [Google Scholar]
  33. Valent P, Akin C, Escribano L, Fodinger M, Hartmann K. 33.  et al. 2007. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur. J. Clin. Invest. 37:435–53 [Google Scholar]
  34. Furitsu T, Tsujimura T, Tono T, Ikeda H, Kitayama H. 34.  et al. 1993. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J. Clin. Invest. 92:1736–44 [Google Scholar]
  35. Bodemer C, Hermine O, Palmerini F, Yang Y, Grandpeix-Guyodo C. 35.  et al. 2010. Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J. Invest. Dermatol. 130:804–15 [Google Scholar]
  36. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD. 36.  et al. 2003. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med 348:1201–14 [Google Scholar]
  37. Lahortiga I, Akin C, Cools J, Wilson TM, Mentens N. 37.  et al. 2008. Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion. Haematologica 93:49–56 [Google Scholar]
  38. Daley T, Metcalfe DD, Akin C. 38.  2001. Association of the Q576R polymorphism in the interleukin-4 receptor α chain with indolent mastocytosis limited to the skin. Blood 98:880–82 [Google Scholar]
  39. Mekori YA, Gilfillan AM, Akin C, Hartmann K, Metcalfe DD. 39.  2001. Human mast cell apoptosis is regulated through Bcl-2 and Bcl-XL. J. Clin. Immunol. 21:171–74 [Google Scholar]
  40. D'Ambrosio C, Akin C, Wu Y, Magnusson MK, Metcalfe DD. 40.  2003. Gene expression analysis in mastocytosis reveals a highly consistent profile with candidate molecular markers. J. Allergy Clin. Immunol. 112:1162–70 [Google Scholar]
  41. Gupta R, Bain BJ, Knight CL. 41.  2002. Cytogenetic and molecular genetic abnormalities in systemic mastocytosis. Acta Haematol 107:123–28 [Google Scholar]
  42. Chaves-Dias C, Hundley TR, Gilfillan AM, Kirshenbaum AS, Cunha-Melo JR. 42.  et al. 2001. Induction of telomerase activity during development of human mast cells from peripheral blood CD34+ cells: comparisons with tumor mast-cell lines. J. Immunol. 166:6647–56 [Google Scholar]
  43. Cherner JA, Jensen RT, Dubois A, O'Dorisio TM, Gardner JD. 43.  et al. 1988. Gastrointestinal dysfunction in systemic mastocytosis. A prospective study. Gastroenterology 95:657–67 [Google Scholar]
  44. Rueff F, Placzek M, Przybilla B. 44.  2006. Mastocytosis and Hymenoptera venom allergy. Curr. Opin. Allergy Clin. Immunol. 6:284–88 [Google Scholar]
  45. Castells M, Metcalfe DD, Escribano L. 45.  2011. Diagnosis and treatment of cutaneous mastocytosis in children: practical recommendations. Am. J. Clin. Dermatol. 12:259–70 [Google Scholar]
  46. Lim KH, Tefferi A, Lasho TL, Finke C, Patnaik M. 46.  et al. 2009. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood 113:5727–36 [Google Scholar]
  47. Hartmann K, Escribano L, Grattan C, Brockow K, Carter MC. 47.  et al. 2016. Cutaneous manifestations in patients with mastocytosis: consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. J. Allergy Clin. Immunol. 137:35–45 [Google Scholar]
  48. Carter MC, Clayton ST, Komarow HD, Brittain EH, Scott LM. 48.  et al. 2016. Assessment of clinical findings, tryptase levels, and bone marrow histopathology in the management of pediatric mastocytosis. J. Allergy Clin. Immunol. 136:1673–79.e3 [Google Scholar]
  49. Brockow K, Scott LM, Worobec AS, Kirshenbaum A, Akin C. 49.  et al. Regression of urticaria pigmentosa in adult patients with systemic mastocytosis: correlation with clinical patterns of disease. Arch. Dermatol. 138:785–90 [Google Scholar]
  50. Williams KW, Metcalfe DD, Prussin C, Carter MC, Komarow HD. 50.  2014. Telangiectasia macularis eruptiva perstans or highly vascularized urticaria pigmentosa?. J. Allergy Clin. Immunol. Pract. 2:813–15 [Google Scholar]
  51. Horny HP, Valent P. 51.  2002. Histopathological and immunohistochemical aspects of mastocytosis. Int. Arch. Allergy Immunol. 127:115–17 [Google Scholar]
  52. Akin C, Valent P, Escribano L. 52.  2006. Urticaria pigmentosa and mastocytosis: the role of immunophenotyping in diagnosis and determining response to treatment. Curr. Allergy Asthma Rep. 6:282–88 [Google Scholar]
  53. Lawrence JB, Friedman BS, Travis WD, Chinchilli VM, Metcalfe DD. 53.  et al. 1991. Hematologic manifestations of systemic mast cell disease: a prospective study of laboratory and morphologic features and their relation to prognosis. Am. J. Med. 91:612–24 [Google Scholar]
  54. Valent P, Akin C, Sperr WR, Horny HP, Metcalfe DD. 54.  2002. Smouldering mastocytosis: a novel subtype of systemic mastocytosis with slow progression. Int. Arch. Allergy Immunol. 127:137–39 [Google Scholar]
  55. Kettelhut BV, Parker RI, Travis WD, Metcalfe DD. 55.  1989. Hematopathology of the bone marrow in pediatric cutaneous mastocytosis. a study of 17 patients. Am. J. Clin. Pathol. 91:558–62 [Google Scholar]
  56. Uzzaman A, Maric I, Noel P, Kettelhut BV, Metcalfe DD. 56.  et al. 2009. Pediatric-onset mastocytosis: a long term clinical follow-up and correlation with bone marrow histopathology. Pediatr. Blood Cancer 53:629–34 [Google Scholar]
  57. Travis WD, Li CY. 57.  1988. Pathology of the lymph node and spleen in systemic mast cell disease. Mod. Pathol. 1:4–14 [Google Scholar]
  58. Horny HP, Kaiserling E, Parwaresch MR, Lennert K. 58.  1992. Lymph node findings in generalized mastocytosis. Histopathology 21:439–46 [Google Scholar]
  59. Horny HP, Ruck MT, Kaiserling E. 59.  1992. Spleen findings in generalized mastocytosis. A clinicopathologic study. Cancer 70:459–68 [Google Scholar]
  60. Mican JM, Di Bisceglie AM, Fong TL, Travis WD, Kleiner DE. 60.  et al. 1995. Hepatic involvement in mastocytosis: clinicopathologic correlations in 41 cases. Hepatology 22:1163–70 [Google Scholar]
  61. Jensen RT. 61.  2000. Gastrointestinal abnormalities and involvement in systemic mastocytosis. Hematol. Oncol. Clin. N. Am. 14:579–623 [Google Scholar]
  62. Chen CC, Andrich MP, Mican JM, Metcalfe DD. 62.  1994. A retrospective analysis of bone scan abnormalities in mastocytosis: correlation with disease category and prognosis. J. Nucl. Med. 35:1471–75 [Google Scholar]
  63. Horan RF, Austen KF. 63.  1991. Systemic mastocytosis: retrospective review of a decade's clinical experience at the Brigham and Women's Hospital. J. Investig. Dermatol. 96:5–14S [Google Scholar]
  64. Travis WD, Li CY, Yam LT, Bergstralh EJ, Swee RG. 64.  1988. Significance of systemic mast cell disease with associated hematologic disorders. Cancer 62:965–72 [Google Scholar]
  65. Sperr WR, Horny HP, Lechner K, Valent P. 65.  2000. Clinical and biologic diversity of leukemias occurring in patients with mastocytosis. Leuk. Lymphoma 37:473–86 [Google Scholar]
  66. Pardanani A, Lim KH, Lasho TL, Finke C, McClure RF. 66.  et al. 2009. Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Blood 114:3769–72 [Google Scholar]
  67. Tefferi A, Elliott MA, Pardanani A. 67.  2006. Atypical myeloproliferative disorders: diagnosis and management. Mayo Clin. Proc. 81:553–63 [Google Scholar]
  68. Valent P, Akin C, Sperr WR, Escribano L, Arock M. 68.  et al. 2003. Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk. Res. 27:635–41 [Google Scholar]
  69. Travis WD, Li CY, Bergstralh EJ. 69.  1989. Solid and hematologic malignancies in 60 patients with systemic mast cell disease. Arch. Pathol. Lab. Med. 113:365–68 [Google Scholar]
  70. Valent P. 70.  1996. Biology, classification and treatment of human mastocytosis. Wien. Klin. Wochenschr. 108:385–97 [Google Scholar]
  71. Valent P, Sotlar K, Sperr WR, Escribano L, Yavuz S. 71.  et al. 2014. Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal. Ann. Oncol. 25:1691–700 [Google Scholar]
  72. Sperr WR, Escribano L, Jordan JH, Schernthaner GH, Kundi M. 72.  et al. 2001. Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis. Leuk. Res. 25:529–36 [Google Scholar]
  73. Horny HP, Parwaresch MR, Kaiserling E, Muller K, Olbermann M. 73.  et al. 1986. Mast cell sarcoma of the larynx. J. Clin. Pathol. 39:596–602 [Google Scholar]
  74. Kojima M, Nakamura S, Itoh H, Ohno Y, Masawa N. 74.  et al. 1999. Mast cell sarcoma with tissue eosinophilia arising in the ascending colon. Mod. Pathol. 12:739–43 [Google Scholar]
  75. Guenther PP, Huebner A, Sobottka SB, Neumeister V, Weissbach G. 75.  et al. 2001. Temporary response of localized intracranial mast cell sarcoma to combination chemotherapy. J. Pediatr. Hematol. Oncol. 23:134–38 [Google Scholar]
  76. Kudo H, Morinaga S, Shimosato Y, Noguchi M, Mizutani Y. 76.  et al. 1988. Solitary mast cell tumor of the lung. Cancer 61:2089–94 [Google Scholar]
  77. Bonadonna P, Perbellini O, Passalacqua G, Caruso B, Colarossi S. 77.  et al. 2009. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. J. Allergy Clin. Immunol. 123:680–86 [Google Scholar]
  78. Akin C, Scott LM, Kocabas CN, Kushnir-Sukhov N, Brittain E. 78.  et al. 2007. Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with “idiopathic” anaphylaxis. Blood 110:2331–33 [Google Scholar]
  79. Akin C, Valent P, Metcalfe DD. 79.  2010. Mast cell activation syndrome: proposed diagnostic criteria. J. Allergy Clin. Immunol. 126:1099–104e4 [Google Scholar]
  80. Valent P, Akin C, Arock M, Brockow K, Butterfield JH. 80.  et al. 2012. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int. Arch. Allergy Immunol. 157:215–25 [Google Scholar]
  81. Schwartz LB. 81.  2001. Clinical utility of tryptase levels in systemic mastocytosis and associated hematologic disorders. Leuk. Res. 25:553–62 [Google Scholar]
  82. Li CY. 82.  2001. Diagnosis of mastocytosis: value of cytochemistry and immunohistochemistry. Leuk. Res. 25:537–41 [Google Scholar]
  83. Akin C, Metcalfe DD. 83.  2002. Surrogate markers of disease in mastocytosis. Int. Arch. Allergy Immunol. 127:133–36 [Google Scholar]
  84. Sperr WR, Jordan JH, Fiegl M, Escribano L, Bellas C. 84.  et al. 2002. Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease. Int. Arch. Allergy Immunol. 128:136–41 [Google Scholar]
  85. Schwartz LB. 85.  2001. Clinical utility of tryptase levels in systemic mastocytosis and associated hematologic disorders. Leuk. Res. 25:553–62 [Google Scholar]
  86. van Toorenenbergen AW, Oranje AP. 86.  2005. Comparison of serum tryptase and urine N-methylhistamine in patients with suspected mastocytosis. Clin. Chim. Acta 359:72–77 [Google Scholar]
  87. Brockow K, Akin C, Huber M, Metcalfe DD. 87.  2005. IL-6 levels predict disease variant and extent of organ involvement in patients with mastocytosis. Clin. Immunol. 115:216–23 [Google Scholar]
  88. Akin C, Schwartz LB, Kitoh T, Obayashi H, Worobec AS. 88.  et al. 2000. Soluble stem cell factor receptor (CD117) and IL-2 receptor alpha chain (CD25) levels in the plasma of patients with mastocytosis: relationships to disease severity and bone marrow pathology. Blood 96:1267–73 [Google Scholar]
  89. Valent P, Sperr WR, Samorapoompichit P, Geissler K, Lechner K. 89.  et al. 2001. Myelomastocytic overlap syndromes: biology, criteria, and relationship to mastocytosis. Leuk. Res. 25:595–602 [Google Scholar]
  90. Dunphy CH. 90.  2005. Evaluation of mast cells in myeloproliferative disorders and myelodysplastic syndromes. Arch. Pathol. Lab. Med. 129:219–22 [Google Scholar]
  91. Sperr WR, Drach J, Hauswirth AW, Ackermann J, Mitterbauer M. 91.  et al. 2005. Myelomastocytic leukemia: evidence for the origin of mast cells from the leukemic clone and eradication by allogeneic stem cell transplantation. Clin. Cancer Res. 11:6787–92 [Google Scholar]
  92. te Velde J, Vismans FJ, Leenheers-Binnendijk L, Vos CJ, Smeenk D, Bijvoet OL. 92.  1978. The eosinophilic fibrohistiocytic lesion of the bone marrow. A mastocellular lesion in bone disease. Virchows Arch. A Pathol. Anat. Histol. 377:277–85 [Google Scholar]
  93. Worobec AS. 93.  2000. Treatment of systemic mast cell disorders. Hematol. Oncol. Clin. N. Am. 14:659–87 [Google Scholar]
  94. Lim KH, Pardanani A, Butterfield JH, Li CY, Tefferi A. 94.  2009. Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am. J. Hematol. 84:790–94 [Google Scholar]
  95. Ustun C, DeRemer DL, Akin C. 95.  2011. Tyrosine kinase inhibitors in the treatment of systemic mastocytosis. Leuk. Res. 35:1143–52 [Google Scholar]
  96. Frieri M, Alling DW, Metcalfe DD. 96.  1985. Comparison of the therapeutic efficacy of cromolyn sodium with that of combined chlorpheniramine and cimetidine in systemic mastocytosis. Results of a double-blind clinical trial. Am. J. Med. 78:9–14 [Google Scholar]
  97. Escribano L, Akin C, Castells M, Schwartz LB. 97.  2006. Current options in the treatment of mast cell mediator-related symptoms in mastocytosis. Inflamm. Allergy Drug Targets 5:61–77 [Google Scholar]
  98. Ravi A, Butterfield J, Weiler CR. 98.  2014. Mast cell activation syndrome: improved identification by combined determinations of serum tryptase and 24-hour urine 11β-prostaglandin2α.. J. Allergy Clin. Immunol. Pract. 2:775–78 [Google Scholar]
  99. Higgins EM, Humphreys S, Duvivier AW. 99.  1994. Urticaria pigmentosa—response to topical steroids. Clin. Exp. Dermatol. 19:438–40 [Google Scholar]
  100. Mackey S, Pride HB, Tyler WB. 100.  1996. Diffuse cutaneous mastocytosis. Treatment with oral psoralen plus UV-A. Arch. Dermatol. 132:1429–30 [Google Scholar]
  101. Stege H, Schopf E, Ruzicka T, Krutmann J. 101.  1996. High-dose UVA1 for urticaria pigmentosa. Lancet 347:64 [Google Scholar]
  102. Godt O, Proksch E, Streit V, Christophers E. 102.  1997. Short- and long-term effectiveness of oral and bath PUVA therapy in urticaria pigmentosa and systemic mastocytosis. Dermatology 195:35–39 [Google Scholar]
  103. Wilson TM, Metcalfe DD, Robyn J. 103.  2006. Treatment of systemic mastocytosis. Immunol. Allergy Clin. N. Am. 26:549–73 [Google Scholar]
  104. Allison MA, Schmidt CP. 104.  1997. Urticaria pigmentosa. Int. J. Dermatol. 36:321–25 [Google Scholar]
  105. Correia O, Duarte AF, Quirino P, Azevedo R, Delgado L. 105.  2010. Cutaneous mastocytosis: two pediatric cases treated with topical pimecrolimus. Dermatol. Online J. 16:8 [Google Scholar]
  106. Achord JL, Langford H. 106.  1980. The effect of cimetidine and propantheline on the symptoms of a patient with systemic mastocytosis. Am. J. Med. 69:610–14 [Google Scholar]
  107. Fonga-Djimi HS, Gottrand F, Bonnevalle M, Farriaux JP. 107.  1995. A fatal case of portal hypertension complicating systemic mastocytosis in an adolescent. Eur. J. Pediatr. 154:819–21 [Google Scholar]
  108. Carter MC, Robyn JA, Bressler PB, Walker JC, Shapiro GG, Metcalfe DD. 108.  2007. Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. J. Allergy Clin. Immunol. 119:1550–51 [Google Scholar]
  109. Johnstone PA, Mican JM, Metcalfe DD, DeLaney TF. 109.  1994. Radiotherapy of refractory bone pain due to systemic mast cell disease. Am. J. Clin. Oncol. 17:328–30 [Google Scholar]
  110. Moret H, Plihal E, Saudan Y. 110.  1994. Case report of bone mastocytosis: total hip arthroplasty for osteoarthritis and open reduction for condylar fracture of the knee. Clin. Rheumatol. 13:619–23 [Google Scholar]
  111. Casassus P, Caillat-Vigneron N, Martin A, Simon J, Gallais V. 111.  et al. 2002. Treatment of adult systemic mastocytosis with interferon-α: results of a multicentre phase II trial on 20 patients. Br. J. Haematol. 119:1090–97 [Google Scholar]
  112. Lehmann T, Beyeler C, Lammle B, Hunziker T, Vock P. 112.  et al. 1996. Severe osteoporosis due to systemic mast cell disease: successful treatment with interferon alpha-2B. Br. J. Rheumatol. 35:898–900 [Google Scholar]
  113. Tefferi A, Li CY, Butterfield JH, Hoagland HC. 113.  2001. Treatment of systemic mast-cell disease with cladribine. N. Engl. J. Med. 344:307–9 [Google Scholar]
  114. Hennessy B, Giles F, Cortes J, O'Brien S, Ferrajoli A. 114.  et al. 2004. Management of patients with systemic mastocytosis: review of M.D. Anderson Cancer Center experience. Am. J. Hematol. 77:209–14 [Google Scholar]
  115. Valent P, Ghannadan M, Akin C, Krauth MT, Selzer E. 115.  et al. 2004. On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts. Eur J. Clin. Invest. 34:Suppl. 241–52 [Google Scholar]
  116. Pardanani A. 116.  2015. Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, and management. Am. J. Hematol. 90:250–62 [Google Scholar]
  117. Nakamura R, Chakrabarti S, Akin C, Robyn J, Bahceci E. 117.  et al. 2006. A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis. Bone Marrow Transpl 37:353–58 [Google Scholar]
  118. Przepiorka D, Giralt S, Khouri I, Champlin R, Bueso-Ramos C. 118.  1998. Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: review of forty cases. Am. J. Hematol. 57:24–28 [Google Scholar]
  119. Ronnov-Jessen D, Lovgreen Nielsen P, Horn T. 119.  1991. Persistence of systemic mastocytosis after allogeneic bone marrow transplantation in spite of complete remission of the associated myelodysplastic syndrome. Bone Marrow Transpl 8:413–15 [Google Scholar]
  120. Ustun C, Gotlib J, Popat U, Artz A, Litzow M. 120.  et al. 2016. Consensus opinion on allogeneic hematopoietic cell transplantation in advanced systemic mastocytosis. Biol. Blood Marrow Transpl. 22:1348–56 [Google Scholar]
  121. Friedman B, Darling G, Norton J, Hamby L, Metcalfe D. 121.  1990. Splenectomy in the management of systemic mast cell disease. Surgery 107:94–100 [Google Scholar]
  122. Ma Y, Zeng S, Metcalfe DD, Akin C, Dimitrijevic S. 122.  et al. 2002. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 99:1741–44 [Google Scholar]
  123. Ueda S, Ikeda H, Mizuki M, Ishiko J, Matsumura I. 123.  et al. 2002. Constitutive activation of C-kit by the juxtamembrane but not the catalytic domain mutations is inhibited selectively by tyrosine kinase inhibitors STI571 and AG1296. Int. J. Hematol. 76:427–35 [Google Scholar]
  124. Akin C, Fumo G, Yavuz AS, Lipsky PE, Neckers L, Metcalfe DD. 124.  2004. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 103:3222–25 [Google Scholar]
  125. Gleixner KV, Mayerhofer M, Aichberger KJ, Derdak S, Sonneck K. 125.  et al. 2006. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood 107:752–59 [Google Scholar]
  126. Gotlib J, Berube C, Growney JD, Chen CC, George TI. 126.  et al. 2005. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 106:2865–70 [Google Scholar]
  127. Shah NP, Lee FY, Luo R, Jiang Y, Donker M, Akin C. 127.  2006. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 108:286–91 [Google Scholar]
  128. Gotlib J, Kluin-Nelemans HC, George TI, Akin C, Stolar K. 128.  et al. 2016. Efficacy and safety of midostaurin in advanced systemic mastocytosis. N. Eng. J. Med. 374:2530–41 [Google Scholar]
  129. Verstovsek S, Tefferi A, Cortes J, O'Brien S, Garcia-Manero G. 129.  et al. 2008. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin. Cancer Res. 14:3906–15 [Google Scholar]
  130. Ustun C, DeRemer DL, Akin C. 130.  2011. Tyrosine kinase inhibitors in the treatment of systemic mastocytosis. Leuk. Res. 35:1143–52 [Google Scholar]
  131. Hochhaus A, Baccarani M, Giles FJ, Le Coputre PD, Muller MC. 131.  et al. 2015. Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open label, single arm nilotinib registration study. J. Cancer Res. Clin. Oncol. 141:2047–60 [Google Scholar]
  132. Blatt K, Cerny-Reiterer S, Schwaab J, Sotlar K, Eisenwort G. 132.  et al. 2015. Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis. Blood 126:2832–41 [Google Scholar]
  133. Pardanani A, Tefferi A. 133.  2010. A critical reappraisal of treatment response criteria in systemic mastocytosis and a proposal for revisions. Eur. J. Haematol. 84:371–78 [Google Scholar]
/content/journals/10.1146/annurev-pathol-052016-100312
Loading
Pathogenesis and Pathology of Mastocytosis
Annual Review of Pathology: Mechanisms of Disease 12, 487 (2017); https://doi.org/10.1146/annurev-pathol-052016-100312
/content/journals/10.1146/annurev-pathol-052016-100312
/content/journals/10.1146/annurev-pathol-052016-100312
Loading

Data & Media loading...

  • Article Type: Review Article

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error